Edesa Biotech, Inc. — Form 10-Q Summary
Reporting period: Three months ended December 31, 2023 (the first quarter of fiscal 2024); comparative period is the three months ended December 31, 2022. The filing is unaudited. Edesa is a clinical-stage biopharmaceutical company and reported no product revenue.
Financial performance and position
| Metric | Quarter ended Dec. 31, 2023 | Quarter ended Dec. 31, 2022 / comparison |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $0.70 million | $1.36 million |
| General and administrative expense | $1.15 million | $1.02 million |
| Operating loss | $1.86 million | $2.38 million |
| Other income | $0.18 million | $0.04 million |
| Net loss | $1.68 million; $0.54 per share | $2.33 million; $0.89 per share |
| Operating cash used | $1.41 million | $1.79 million |
| Cash and cash equivalents | $4.27 million at Dec. 31, 2023 | $5.36 million at Sept. 30, 2023; $8.27 million at Dec. 31, 2022 |
| Working capital | $3.4 million at Dec. 31, 2023 | Not stated for the comparable quarter |
Operating expenses fell by about $0.5 million year over year, primarily because EB01 study-related external research spending declined after that study was completed. G&A rose mainly from professional fees and noncash share-based compensation. Other income included $0.12 million of reimbursement grant income and $0.06 million of interest income. No significant capital expenditures or investing cash flows were reported. As a development-stage company without product revenue, conventional revenue margins are not meaningful.
At December 31, 2023, total assets were $7.83 million, total liabilities $1.99 million, and shareholders’ equity $5.84 million. Liabilities consisted principally of accounts payable and accrued liabilities of $1.91 million and current lease liabilities of $0.08 million; no credit-facility advances were outstanding. Cash declined by $1.09 million during the quarter. The company raised approximately $0.3 million net through its ATM offering and used $1.41 million in operating cash.
Business developments, outlook and risks
- Pipeline: EB05 is in an ongoing Phase 3 study for ARDS; recruitment is ongoing. Health Canada approved harmonization of U.S. and Canadian trial designs. The company is also exploring evaluation of EB05 in all-cause ARDS. In November 2023, Edesa reported that 1.0% EB01 cream showed statistically significant improvement over placebo on the Phase 2b study’s primary and a key secondary endpoint. Health Canada approved a future EB06 Phase 2 study, and the company is preparing a U.S. IND for EB07.
- Funding and liquidity: Management expects to fund operations over the next 12 months with cash on hand, ATM proceeds, potential advances under its credit facility and eligible reimbursements under the 2023 Canadian Strategic Innovation Fund agreement. The company says it expects substantial operating losses for at least several more years and may need additional capital; funding may not be available on acceptable terms or at all. Failure to secure funding could delay, reduce or stop development programs.
- Government funding: The 2023 SIF agreement provides up to C$23 million for EB05-related work and safety studies. Up to C$5.8 million is nonrepayable; C$17.2 million is conditionally repayable beginning in 2029 if the company earns gross revenue, subject to agreement terms. Funding is subject to covenants and default remedies, including possible suspension or termination and repayment demands.
- Related-party credit: An unsecured revolving facility with an entity controlled by the CEO has a stated $3.5 million credit limit, but advances are also capped at 85% of the borrowing base. It bears interest at the CIBC U.S. Base-Interest Rate plus 3%, matures March 31, 2026, and was undrawn at quarter-end. The filing also reports a $12,000 standby charge for the quarter.
- Commitments and contingencies: Contracted research and other future payments totaled approximately $1.67 million, of which $1.54 million was scheduled for fiscal 2024. Separate license agreements include potential milestone obligations of up to $356 million, $18.4 million and $68.9 million, plus royalties or sublicensing payments; these are contingent, not current debt. A $25,000 expense was recorded for a milestone under one license in the quarter.
- Other risks: Key risks include clinical-trial outcomes and timing, regulatory approval, financing needs, dilution, competition, intellectual-property and license obligations, and foreign-exchange exposure. The company does not hedge currency risk; it estimated that a 10% annual change in the Canadian/U.S. exchange rate could affect loss and comprehensive loss by about $0.1 million. No material changes to the prior annual-report risk factors or material legal proceedings were reported. Management concluded disclosure controls were effective and reported no material internal-control changes.
Most important facts for investors to verify
- Progress, enrollment and results of the EB05 Phase 3 study, and any plans for all-cause ARDS evaluation.
- Whether the 2023 SIF agreement reimbursements are received as expected, and the conditions attached to the repayable funding.
- Cash consumption, committed clinical spending and whether available funding can support operations beyond management’s stated 12-month planning horizon.
- Actual usable capacity and borrowing-base availability under the CEO-related credit facility, as well as ATM issuance and resulting dilution.
- Development timelines and regulatory progress for EB01, EB06 and EB07, including the implications of future license milestones and royalties.
Subsequent to quarter-end, Edesa reported issuing 7,038 ATM shares for approximately $33,000 in net proceeds. The filing does not provide a precise cash-runway date.